CCCC
C4 Therapeutics, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Neutral
-20/100
Last price
2.93
▼ 0.06 (2.01%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
2.99
Prev close
2.99
Day high
3.03
Day low
2.79
Volume
2.11M
Market cap
$354.31M
P/E (TTM)
—
52W range
1.69 – 5.17
Day trading desk
Gap from prior close
-0.00%
Prior close 2.99
VWAP
2.88
+1.79% from price
Relative volume
1.51×
Unusually busy
Session range
11.11%
2.79 – 3.10
Position in range
45%
Mid range
ATR (14D)
0.22
7.53% of price
Prior day high
3.10
PDH
Prior day low
2.95
PDL
Bid / ask spread
—
Quote not published
Session volume
3.71M
Avg 2.46M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-7.99%
-9.9%
1M
-23.40%
-24.6%
3M
-31.26%
-35.8%
6M
+5.11%
-13.1%
YTD
+50.79%
+36.5%
1Y
+26.87%
+10.5%
3Y
+54.84%
-27.4%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on CCCC open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
1.04M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 18, 26 | ADAMS KENDRA Chief Financial Officer |
— | 6.25K | — | Direct |
| Jul 10, 26 | REYNO LEONARD Officer |
— | 15.32K | — | Direct |
| Jul 1, 26 | GROGAN DONNA ROY M.D. Director |
STOCK | 3.34K | $14.50K | Direct |
| Jul 1, 26 | ANDERSON KENNETH CARL Director |
STOCK | 2.65K | $11.50K | Direct |
| Jun 1, 26 | ANDERSON KENNETH CARL Director |
CONVERSION | 1.07K | $2.26K | Direct |
| Apr 1, 26 | GROGAN DONNA ROY M.D. Director |
STOCK | 5.37K | $14.50K | Direct |
| Apr 1, 26 | ANDERSON KENNETH CARL Director |
STOCK | 4.26K | $11.50K | Direct |
| Feb 13, 26 | HIRSCH ANDREW Chief Executive Officer |
STOCK | 700.00K | $0 | Direct |
| Feb 13, 26 | HIRSCH ANDREW Chief Executive Officer |
— | 102.13K | — | Direct |
| Feb 13, 26 | REYNO LEONARD Officer |
STOCK | 240.00K | $0 | Direct |
| Feb 13, 26 | REYNO LEONARD Officer |
— | 30.95K | — | Direct |
| Feb 13, 26 | SCHICK KELLY Officer |
STOCK | 200.00K | $0 | Direct |
| Feb 13, 26 | SCHICK KELLY Officer |
— | 25.95K | — | Direct |
| Feb 13, 26 | BOYLE SCOTT N Officer |
STOCK | 200.00K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ADAMS KENDRA |
Chief Financial Officer | 382.32K | Conversion of Exercise of derivative security |
ANDERSON KENNETH CARL |
Director | 358.24K | Stock Award(Grant) |
BOYLE SCOTT N |
Officer | 298.80K | Stock Award(Grant) |
GROGAN DONNA ROY M.D. |
Director | 74.85K | Stock Award(Grant) |
HIRSCH ANDREW |
Chief Executive Officer | 1.07M | Stock Award(Grant) |
MAHANEY PAIGE |
Officer | 336.91K | Stock Award(Grant) |
MOSSLER MARK |
Officer | 71.92K | Stock Award(Grant) |
REYNO LEONARD |
Officer | 372.41K | Conversion of Exercise of derivative security |
SCHICK KELLY |
Officer | 299.88K | Stock Award(Grant) |
SIEGEL JOLIE M. |
Officer | 107.94K | Stock Award(Grant) |
Fundamentals
Market cap$354.31M
Enterprise value$157.51M
Revenue (TTM)$35.04M
Gross profit$30.25M
EBITDA$-99.45M
Net income$-101.42M
EPS (TTM)$-0.88
Free cash flow$-43.66M
Total cash$253.66M
Total debt$56.86M
Book value / share$2.01
Shares outstanding123.03M
Float94.50M
Short % of float32.86%
Dividend yield0.00%
Beta (5Y)3.08
Valuation & profitability ratios
Trailing P/E—
Forward P/E-2.89
PEG ratio—
Price / sales—
Price / book1.43
EV / revenue4.50
EV / EBITDA-1.58
Gross margin86.34%
Operating margin-397.88%
Profit margin-289.44%
Return on equity-48.14%
Return on assets-19.25%
Debt / equity23.00
Current ratio5.45
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $35.95M | $35.58M | $20.76M | $31.10M | +1.0% |
| Operating revenue | $35.95M | $35.58M | $20.76M | $31.10M | +1.0% |
| Research & development | $104.24M | $110.64M | $117.71M | $117.84M | -5.8% |
| Selling, general & admin | $36.20M | $42.12M | $42.08M | $42.79M | -14.1% |
| Total operating expense | $140.44M | $152.76M | $159.79M | $160.63M | -8.1% |
| Operating income | -$104.49M | -$117.18M | -$139.03M | -$129.53M | +10.8% |
| Net interest income | $10.35M | $14.43M | $8.44M | $1.36M | -28.3% |
| Pre-tax income | -$104.87M | -$105.19M | -$131.21M | -$128.18M | +0.3% |
| Tax provision | $121.00K | $131.00K | $1.28M | $0 | -7.6% |
| Net income | -$104.99M | -$105.32M | -$132.49M | -$128.18M | +0.3% |
| Net income to common | -$104.99M | -$105.32M | -$132.49M | -$128.18M | +0.3% |
| Basic EPS | -1.27 | -1.52 | -2.67 | -2.62 | +16.4% |
| Diluted EPS | -1.27 | -1.52 | -2.67 | -2.62 | +16.4% |
| EBIT | -$104.49M | -$117.18M | -$129.84M | -$125.96M | +10.8% |
| EBITDA | -$102.53M | -$115.36M | -$127.96M | -$124.28M | +11.1% |
| Basic shares | 82.89M | 69.37M | 49.64M | 48.86M | +19.5% |
| Diluted shares | 82.89M | 69.37M | 49.64M | 48.86M | +19.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $74.60M | $55.50M | $126.59M | $29.75M | — | +34.4% |
| Cash & short-term investments | $248.54M | $244.90M | $253.68M | $276.15M | — | +1.5% |
| Accounts receivable | $2.40M | $3.10M | $11.80M | $1.47M | — | -22.6% |
| Total current assets | $258.11M | $257.77M | $271.19M | $287.56M | — | +0.1% |
| Property, plant & equipment | $45.28M | $63.38M | $71.09M | $77.52M | — | -28.6% |
| Total assets | $359.07M | $349.60M | $376.45M | $430.84M | — | +2.7% |
| Total current liabilities | $33.03M | $45.18M | $42.77M | $44.55M | — | -26.9% |
| Current debt | — | — | — | $2.29M | — | — |
| Long-term debt | — | — | — | $9.20M | $10.77M | — |
| Total debt | $59.98M | $65.76M | $70.98M | $87.15M | — | -8.8% |
| Total liabilities | $102.49M | $133.62M | $130.34M | $141.61M | — | -23.3% |
| Retained earnings | -$738.69M | -$633.70M | -$528.38M | -$395.89M | — | -16.6% |
| Shareholder equity | $256.59M | $215.99M | $246.11M | $289.23M | — | +18.8% |
| Working capital | $225.08M | $212.59M | $228.42M | $243.01M | — | +5.9% |
| Net tangible assets | $256.59M | $215.99M | $246.11M | $289.23M | — | +18.8% |
| Shares issued | 96.91M | 70.63M | 60.47M | 48.97M | — | +37.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$104.99M | -$105.32M | -$132.49M | -$128.18M | +0.3% |
| Depreciation & amortisation | $1.96M | $1.82M | $1.88M | $1.68M | +7.8% |
| Stock-based compensation | $19.10M | $29.66M | $27.23M | $30.02M | -35.6% |
| Change in working capital | -$29.28M | $7.65M | -$6.94M | -$16.78M | -482.9% |
| Operating cash flow | -$98.69M | -$65.16M | -$106.84M | -$105.94M | -51.5% |
| Capital expenditure | -$607.00K | -$180.00K | -$1.71M | -$5.50M | -237.2% |
| Investing cash flow | -$8.60M | -$51.27M | $158.35M | $58.42M | +83.2% |
| Share buybacks | -$193.00K | -$194.00K | -$110.00K | $0 | +0.5% |
| Financing cash flow | $126.40M | $45.34M | $45.49M | $1.15M | +178.8% |
| Free cash flow | -$99.30M | -$65.34M | -$108.55M | -$111.44M | -52.0% |
| End cash position | $78.05M | $58.94M | $130.03M | $33.03M | +32.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $6.64M | $6.15M | $11.02M | $11.23M | $6.46M | +7.9% |
| Operating revenue | $6.64M | $6.15M | $11.02M | $11.23M | $6.46M | +7.9% |
| Research & development | $24.47M | $24.61M | $24.98M | $25.99M | $26.20M | -0.5% |
| Selling, general & admin | $8.59M | $9.33M | $9.18M | $8.92M | $8.77M | -7.9% |
| Total operating expense | $33.06M | $33.94M | $34.16M | $34.91M | $34.96M | -2.6% |
| Operating income | -$26.42M | -$27.79M | -$23.14M | -$23.68M | -$28.50M | +4.9% |
| Net interest income | $2.79M | $2.66M | $2.78M | $2.25M | $2.48M | +5.0% |
| Pre-tax income | -$23.64M | -$25.13M | -$20.36M | -$32.17M | -$26.02M | +5.9% |
| Net income | -$23.64M | -$25.13M | -$20.49M | -$32.17M | -$26.02M | +5.9% |
| Net income to common | -$23.64M | -$25.13M | -$20.49M | -$32.17M | -$26.02M | +5.9% |
| Basic EPS | -0.18 | -0.20 | -0.18 | -0.44 | -0.37 | +10.0% |
| Diluted EPS | -0.18 | -0.20 | -0.18 | -0.44 | -0.37 | +10.0% |
| EBIT | -$26.42M | -$27.79M | -$23.14M | -$23.68M | -$28.50M | +4.9% |
| EBITDA | -$26.13M | -$27.38M | -$22.72M | -$23.22M | -$27.89M | +4.6% |
| Basic shares | 130.70M | 126.07M | 116.78M | 72.56M | 71.01M | +3.7% |
| Diluted shares | 130.70M | 126.07M | 116.78M | 72.56M | 71.01M | +3.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $78.61M | $61.27M | $74.60M | $58.81M | $78.16M | +28.3% |
| Cash & short-term investments | $253.66M | $235.67M | $248.54M | $191.88M | $214.55M | +7.6% |
| Accounts receivable | $1.33M | $2.88M | $2.40M | $6.54M | $2.16M | -53.7% |
| Total current assets | $262.90M | $245.37M | $258.11M | $206.86M | $224.73M | +7.1% |
| Property, plant & equipment | $41.79M | $43.58M | $45.28M | $47.09M | $59.76M | -4.1% |
| Total assets | $359.40M | $328.86M | $359.07M | $265.49M | $296.53M | +9.3% |
| Total current liabilities | $48.25M | $27.25M | $33.03M | $35.95M | $44.46M | +77.1% |
| Total debt | $56.86M | $58.45M | $59.98M | $61.46M | $62.92M | -2.7% |
| Total liabilities | $112.14M | $94.61M | $102.49M | $111.08M | $122.46M | +18.5% |
| Retained earnings | -$787.46M | -$763.82M | -$738.69M | -$718.21M | -$686.04M | -3.1% |
| Shareholder equity | $247.26M | $234.25M | $256.59M | $154.41M | $174.06M | +5.6% |
| Working capital | $214.66M | $218.12M | $225.08M | $170.92M | $180.27M | -1.6% |
| Net tangible assets | $247.26M | $234.25M | $256.59M | $154.41M | $174.06M | +5.6% |
| Shares issued | 122.91M | 104.04M | 96.91M | 74.17M | 71.01M | +18.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$23.64M | -$25.13M | -$20.49M | -$32.17M | -$26.02M | +5.9% |
| Depreciation & amortisation | $292.00K | $404.00K | $428.00K | $460.00K | $615.00K | -27.7% |
| Stock-based compensation | $3.04M | $2.67M | $4.01M | $4.59M | $4.99M | +13.7% |
| Change in working capital | $17.45M | -$8.27M | -$6.68M | -$16.03M | $7.25M | +311.0% |
| Operating cash flow | -$1.57M | -$29.94M | -$22.14M | -$31.21M | -$12.06M | +94.7% |
| Capital expenditure | -$37.00K | -$64.00K | -$11.00K | -$411.00K | — | +42.2% |
| Investing cash flow | -$14.81M | $16.15M | -$80.73M | $4.09M | $38.92M | -191.7% |
| Share buybacks | $0 | -$200.00K | -$14.00K | -$24.00K | $0 | +100.0% |
| Financing cash flow | $33.73M | $462.00K | $118.67M | $7.77M | $0 | +7,199.8% |
| Free cash flow | -$1.61M | -$30.01M | -$22.16M | -$31.62M | -$12.24M | +94.6% |
| End cash position | $82.05M | $64.72M | $78.05M | $62.25M | $81.60M | +26.8% |
Options analytics
Put / call volume
0.16
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
5.00
+73.6% from spot
ATM implied vol
12.5%
Nearest strike to spot
Skew (10% OTM)
-12.5%
Calls bid over puts
Call volume
164
Contracts, this expiry
Put volume
26
Contracts, this expiry
Heaviest call OI
0.50
0 contracts
Heaviest put OI
1.00
13 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.23 | -0.18 | +21.7% |
| Mar 2026 | -0.26 | -0.20 | +23.1% |
| Dec 2025 | -0.39 | -0.18 | +54.2% |
| Sep 2025 | -0.39 | -0.30 | +24.6% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.22 | 4 | $8.82M | -21.5% |
| Next quarter | -0.27 | 4 | $4.00M | -63.7% |
| Current year | -0.89 | 4 | $25.74M | -28.4% |
| Next year | -1.00 | 4 | $20.54M | -20.2% |
Analyst targets & ownership
Mean target$13.33
High target$30.00
Low target$7.00
Implied upside355.06%
Analyst count6
ConsensusSTRONG BUY
Strong buy / Buy1 / 6
Hold0
Sell / Strong sell0 / 0
Held by insiders0.84%
Held by institutions103.09%
Institutions holding199
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
3.06
-4.33% from price
SMA 20
3.24
-10.97% from price
SMA 50
3.61
-20.14% from price
SMA 100
3.75
-21.91% from price
SMA 200
3.12
-7.77% from price
EMA 12
3.12
-6.10% from price
EMA 26
3.32
-11.63% from price
EMA 50
3.49
-15.96% from price
RSI (14)
33.0
Neutral
MACD (12,26,9)
-0.20
Hist -0.02
ATR (14)
0.22
7.66% of price
Realised vol 30D
52.5%
Annualised
Bollinger upper
3.63
20, 2σ
Bollinger lower
2.84
20, 2σ
50 / 200 cross
Golden
3.61 vs 3.12
Trend bias
Below 200
-7.77%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.78
More volatile than market
Correlation to SPY
0.28
Largely independent
Realised vol 30D
52.5%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-39.1%
Peak to trough
Max drawdown 5Y
-97.7%
Peak to trough
ATR 14
0.22
7.66% of price
Beta (reported)
3.08
5Y monthly, from filing
Short interest
Shares short
40.19M
Prior 34.05M
Change vs prior
+18.0%
Shorts adding
% of float
32.86%
Heavily shorted
% of shares out
32.67%
Against total outstanding
Days to cover
19.8
Crowded exit
Float
94.50M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 1, 26 | Evercore ISI Group | MAINTAINED | Outperform | Outperform |
| Feb 27, 26 | Barclays | MAINTAINED | Overweight | Overweight |
| Feb 23, 26 | Brookline Capital | MAINTAINED | Buy | Buy |
| Dec 17, 25 | Barclays | MAINTAINED | Overweight | Overweight |
| Dec 2, 25 | TD Cowen | INITIATED | — | Buy |
| Sep 23, 25 | Wells Fargo | MAINTAINED | Overweight | Overweight |
| Sep 23, 25 | Barclays | MAINTAINED | Overweight | Overweight |
| Sep 22, 25 | Stephens & Co. | MAINTAINED | Overweight | Overweight |
| Sep 17, 25 | Barclays | INITIATED | — | Overweight |
| Sep 15, 25 | Stephens & Co. | UPGRADE | Equal-Weight | Overweight |
| Sep 4, 25 | Guggenheim | INITIATED | — | Buy |
| Dec 19, 24 | Wells Fargo | UPGRADE | Equal-Weight | Overweight |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-25
Corporate Changes & Voting Matters
8-K · 2026-08-11
Corporate Changes & Voting Matters
8-K · 2026-06-24
Corporate Changes & Voting Matters
8-K · 2026-06-11
Corporate Changes & Voting Matters
8-K · 2026-05-15
Corporate Changes & Voting Matters
8-K · 2026-05-12
Proxy Statements
DEF 14A · 2026-04-29
Corporate Changes & Voting Matters
8-K · 2026-04-10
Headlines
C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting
GlobeNewswire · 12d ago
Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?
Zacks · 14d ago
C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual Meeting
GlobeNewswire · 34d ago
Are You Looking for a Top Momentum Pick? Why C4 Therapeutics, Inc. (CCCC) is a Great Choice
Zacks · 47d ago
C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates
Zacks · 57d ago
C4 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
GlobeNewswire · 57d ago
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 57d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.